semaglutide 2.4 mg obesity FDA approves drug that helped people cut weight 15% The evolving landscape of obesity

Exenatide led to a rapid ICP reduction: mean opening pressure decreased by 5.7 cmCSF at 2.5 h post-dose (placebo-corrected difference

Which is exactly why so many women have absolutely no idea what is causing it

06/05/25 RxOutlook - 2nd Quarter 2025 01/17/25 Lumakras (sotorasib) plus Vectibix (panitumumab) New indication January 17, 2025 - Amgen announced the FDA approval of Lumakras (sotorasib), in combination with Vectibix (panitumumab), for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy

Animal studies have demonstrated that GLP-1 receptor activation can reduce preference for palatable, high-sugar foods and decrease reward-driven eating behaviours

It is expected to be a prescription-only medicine, like other weight-loss medications, meaning it will only be available with a doctor's prescription

These side effects usually go away over time as your body gets used to the medication and dosage